Archive for the ‘Gene Therapy Research’ Category

EPXBody finally helps to lose weight even without diet
Building a brand that can change the future of literally millions of people is not something that we take lightly. EPXbody was founded by Dan Putnam with the vision of teaching people that your past does not have to equal your future. You have control over our health and wealth and now with EPXbody you can have the vehicle to reach your goals. EPX is short for Epigenetics; science has shown that with proper nutrition, diet and exercise, you can improve your genetics and the genetics of generations to follow. Not only do we feel that our products can change your health but we also know there is an urgent need for people to improve their financial health as well. Our vision as a company is to impact our members #39; health and wealth positively by providing them with the best nutritional products, diet and exercise information, as well as all the tools and training needed to build a successful home-based business. This will allow our members to improve their own lives as well as the people they know love and care about. win 1000 bucks monthly just for watching this short video: http://www.getepx.com/successmaker It will ask for your name, e-mail and tel. no to direct you to the videoFrom:Paula GerendásViews:0 0ratingsTime:02:49More inPeople Blogs

Visit link:
EPXBody finally helps to lose weight even without diet - Video

BSA ND3
Get a great deal here redirect.viglink.com?key=1f0527e04637dcdb26bf99b11836bfbf out=http%3A%2F%2Fwww%2Eamazon%2Ecom%2Fdp%2FB005KU1NQU Product Description BSA ND3 The ND-3® x50 Laser Designator is the latest precision optical lighting instrument from Laser Genetics using advanced green laser technology. It is equipped with a 50mm lens and the strongest laser that we have ever manufactured for this application. The patented Rotary Optical Collimator allows full easy adjustment and control of the beam diameter and intensity to focus light where you need it most. Rotating the collimator provides a range of illumination, enough to light a trail or pursue a target in close quarters at night or paint a target up to 500 yards*! Specifications - Precision machined from high tech aluminum - Black matte anodized finish - Fully O-Ring sealed for dust and water - Fully Multi-Coated optical lens system - Nitrogen charged for anti-fog - 1" Tube adapts to multiple mounting systems - Dimensions: 9.45"LX 2.35" Dia. X 1.0" Dia. Tube - Weight: 13.5 OZ. - Power Supply: 2 CR123A Batteries (Incl.) - Output Power: 40mW - Rotary optical beam collimator - allows quick adjustment of beam diameter and intensity - 532nm (Green) Laser light frequency - easiest light for the human eye to see (See Chart) - Amplified coherent light - most efficient light for long distance illumination - RANGE: UP TO 5.0 MILES (Range might vary depending on weather conditions) - 1 Year warranty - FDA Safety Class: 2M ...From:lurlene logueViews:0 0ratingsTime:00:52More inScience Technology

Link:
BSA ND3 - Video

Dr. Rick Kaht Teacher of the Year for Cobb County picks up his New Honda Pilot
Dickerson Middle School #39;s Dr. Richard Kaht aims to get his students excited about exploring science, using humor and hands-on reinforcement. Dr. Kaht said, "If students do not enjoy my Life Science class, it will be that much harder for them to learn the material and take ownership in the concepts." For example, after discussing Gregor Mendel #39;s study of genetics by growing peas, students grew their own peas in the classroom. "I try to not only teach a subject, but also present skills of learning and the idea that they can be successful and accomplish great things." During the 2011-2012 school year, Dr. Kaht started Dickerson #39;s FTC Robotics Club for students as a fun, extracurricular extension of the science concepts covered during class time. In its first year, the team competed against teams of high school students and earned two top ten finishes. Since joining Dickerson in 1999, Dr. Kaht has participated in the DMS Leadership Team, helped implement the Olweus Bullying Prevention program and collaborated with other science teachers to improve instruction throughout Cobb CountyFrom:EdVoylesHondaViews:0 0ratingsTime:00:51More inEducation

See the rest here:
Dr. Rick Kaht Teacher of the Year for Cobb County picks up his New Honda Pilot - Video

Hcg Diet Guide - A Revolution In Weight Loss
xxsurl.com Hcg Diet Guide - A Revolution In Weight Loss HCG is a revolution in weight loss, and the HCG Guide is your step by step guide to implementing the HCG Diet, including tips and tricks you won #39;t find anywhere else. HCG Diet Guide - A Revolution in Weight Loss If you #39;ve heard of HCG, then you already know how powerful it is for weight loss. If you haven #39;t heard of HCG, click here. This guide will take you through every step of the way of how to implement the HCG diet. You will learn: Why HCG works. Where to get HCG. What #39;s the best way to administer HCG for you. The easiest way to do this diet. Step by step instructions. What supplies you will need for the HCG diet, and where to get them. Each phase of the diet in detail. What #39;s new to the diet since it came out over 40 years ago. Trouble shooting problems. Tips and tricks on every aspect of the diet. Tips and tricks to effortlessly maintain your weight loss. And much much more. And if we #39;ve left anything out, you can contact us as long as you need to, and have all your questions aswered. If you haven #39;t heard of HCG, and you have struggled to lose weight, then you will remember this day as the day that changed your life forever. Why can some people eat whatever they want, whenever they want, and they donAt gain weightb And they donAt even exercise! Most people will say itAs genetics, but thatAs not true. The truth of the matter is, your body is screwed up. What screwed it upb Diets. ThatAs right, the more diets ...From:melissahannah326Views:0 0ratingsTime:01:44More inPeople Blogs

Read the rest here:
Hcg Diet Guide - A Revolution In Weight Loss - Video

How To Grow Taller?
http://www.growth-flex.com - How to grow taller? Most short people often tend to lack confidence and self-esteem more than those of average height because they feel like they are "below" the average height in sports, career or even finding a love partner. "Genetics and nutrition have the biggest impact on your height. How much of human height is genetic and how much is due to nutrition? About 60 to 80 percent of our difference in height between individuals is determined by genetic factors, whereas 20 to 40 percent can be attributed to environmental effects, mainly nutrition". Learn how to grow taller without the needs for expensive surgeries. For more information please visitFrom:TallerGrowNowViews:0 0ratingsTime:00:34More inHowto Style

Read the original:
How To Grow Taller? - Video

Gene Jones
Gene Jones: Mutation Hunter A short film made as part of a two day workshop on science communication. This is what happens when four scientists are told to explain their research, given a camera and eight hours to make a film... Thanks to Genetics Otago, The Centre for Science Communication and our tutor Steve Ting.From:TheRocketGrrrlViews:13 0ratingsTime:02:33More inMusic

Read this article:
Gene Jones - Video

How to Effectively Structure and Use Board of Directors/Advisers
In this workshop, we #39;ll discuss how to build a Board and get the most out of it, including strategy and considerations for selecting, utilizing and compensating Directors and Advisors. About the speaker: Chad Stiening of Mentor Management is a University of Illinois graduate (Class of #39;99, BS Biology, BS Finance) who is currently running a medical diagnostic device company, Kypha, Inc., located at the BioGenerator Accelerator Labs in St. Louis. He has a PhD in Molecular Genetics from the University of Arizona, and previously worked as a business development executive at the University of Louisville-affiliated Research Park and Innovation Center, NUCLEUS. He is passionate about University of Illinois and helping entrepreneurs with the practical work needed to advance life science start-ups and technology commercialization, from market analysis and regulatory planning to early-stage financing and growth strategies.From:researchparkuiucViews:0 0ratingsTime:01:03:06More inScience Technology

See the original post here:
How to Effectively Structure and Use Board of Directors/Advisers - Video

Savage Genetics -Silent Hill(Tyler Terror REMIX)
Facebook: http://www.facebook.com Welcome to Silent Hill! Original Song: Savage Genetics - Silent Hill Silent Hill belongs to Konami, I do not own the game or movies in any way, nor the original song, just the remix. If you enjoyed, please like and subscribe. 2012, T0XiiCKANDY Studios, all rights reserved.From:RumagrizzViews:1 0ratingsTime:03:48More inMusic

Go here to read the rest:
Savage Genetics -Silent Hill(Tyler Terror REMIX) - Video

Cool Cell
Pure York Premium Blend GeneticsFrom:lairdhampsViews:19 0ratingsTime:00:39More inPets Animals

Excerpt from:
Cool Cell - Video

Alzheimer #39;s Gene Trem2 Variant Discovered by BYU, International Research Team
BYU plays major role in discovery of new Alzheimer #39;s risk gene;Global study suggests immune response plays key role in Alzheimer #39;s development Scientists at BYU and several other leading Alzheimer #39;s research institutions have discovered a rare genetic mutation that increases the risk of Alzheimer #39;s disease. The international team of researchers report in this week #39;s issue of the New England Journal of Medicine that a rare variant of TREM2, a gene associated with the immune system, is linked to a higher risk of Alzheimer #39;s. The study, which used genetic data from more than 25000 people, suggests that problems with the immune system could be a key player in the development of Alzheimer #39;s. "Discovering a new gene for Alzheimer #39;s disease is major step in learning about the genes, proteins and biological pathways that actually cause disease," said BYU geneticist John "Keoni" Kauwe, a co-author on the study. "And that #39;s what we need to know to come up with ways to prevent or cure Alzheimer #39;s." Treatments for the disease have been unsuccessful because by the time a person is diagnosed, the disease has already been crippling the brain for years. Scientists like Kauwe are doing the science behind future diagnostic tests that will hopefully predict Alzheimer #39;s five, 10 or 15 years before onset. Kauwe #39;s BYU team provided the initial validation of the discovery and contributed more than 200 complete human genomes to the study. Ph.D. student Perry Ridge did the analysis of the whole ...From:BYUNewsViews:6 0ratingsTime:01:36More inScience Technology

More here:
Alzheimer's Gene Trem2 Variant Discovered by BYU, International Research Team - Video

Discovery Presents Dinosaurs Return to Life .
Discovery Channel presents the premiere of Dinosaurs: Return to Life, a startling one-hour special that virtually turns back the clock to the Jurassic period and recreates the dinosaurs that ruled the planet 200 million years ago. Through rapid advances in genetics, scientists are discovering the genetic traits of dinosaurs in the DNA of birds. They are showing that it is possible to bring back teeth, long tails and hands in place of wings. In Dinosaurs: Return to Life, learn why the dream of recreating the dinosaur genome is coming closer to reality.From:TheFlorinmartinezViews:4 0ratingsTime:43:32More inScience Technology

See more here:
Discovery Presents Dinosaurs Return to Life . - Video

Billy Ray Meet Illana Rudnick
My cousin Illana Runick is Billy Ray Cyrus #39;s biggest fan. She has a genetic disorder called cri du chat. I (Katelyn Cordero) have been trying for the last few years to get her to meet him but have come up unsuccessful. I am looking for anyone who can help me to grant my cousin #39;s wish! For more information on Cri Du Chat you can take a look at these websites: http://www.fivepminus.org learn.genetics.utah.edu http://www.genome.gov en.wikipedia.orgFrom:95kcorderoViews:0 0ratingsTime:04:04More inEntertainment

Go here to see the original:
Billy Ray Meet Illana Rudnick - Video

Learn How To Quickly and Permanently Eradicate Your Autoimmune Disease
Learn How To Quickly and Permanently Eradicate Your Autoimmune Disease. tinyurl.com For several years, genetics has been the absolutely no. 1 explanation traditional medicinal practises is offering for autoimmunity development. Nonetheless it will not explain why one child from a mother develops an autoimmune disease once the other five never obtain it. No, all disease have a very distinctive span of development and now, for the first time ever, one can learn what exactly is it about yourself that made you afflicted with a change inside immune response. It is important to realize that autoimmunity never goes alone. It causes all sort of disturbances withinside the normal functioning with the body as it initiates a vicious cycle of hormonal changes, enzyme disruptions and organ malfunctions. The Autoimmunity Bible Norton Protocol, This breakthrough product is the only system around that provides you the capacity to: [ 1 ] For the first time ever, pinpoint the underlying reasons for your condition and know very well what is going on [ 2 ] Heal your disease permanently [ 3 ] Eliminate the culprits of the pain completely inside two weeks [ 4 ] Heal your disease holistically. When you have tried different diets, potions and drugs the traditional medicine recommends, you realize chances are which they simply fail or that they #39;re a "fast solution" before your pain comes home having a vengeance. [ 5 ] Heal your disease minus the horrible side effects of conventional drugs. An ...From:Mr4anewwayViews:0 0ratingsTime:01:38More inHowto Style

See the original post here:
Learn How To Quickly and Permanently Eradicate Your Autoimmune Disease - Video

NEET ACADEMY - Genetics Paediatrics
From:neetacademyViews:0 0ratingsTime:08:01More inEntertainment

Original post:
NEET ACADEMY - Genetics Paediatrics - Video

Centenary Institute Lawrence Creative Prize 2012
The winner of the Centenary Institute Lawrence Creative Prize is Dr Jian Yang, from the Diamantina Institute of the University of Queensland. He has solved one of the great puzzles of human genetics mdash;why the genes typically implicated in inherited diseases like schizophrenia, obesity and diabetes only account for a small amount of their heritability. Read more about his great achievement here: bit.lyFrom:CentenaryInstituteViews:5 0ratingsTime:02:15More inScience Technology

Originally posted here:
Centenary Institute Lawrence Creative Prize 2012 - Video

Genetics of a Modified Operation - GMO Documentary
From:Alejandro MuñozViews:0 0ratingsTime:16:37More inPeople Blogs

Read the original here:
Genetics of a Modified Operation - GMO Documentary - Video

Carb Cycling Diet | 4 Cycle Fat Loss Solution Review
Carb cycling diet is a proven technique that is particularly ideal for men in the 10-15 percent body fat range. The technique involves preserving muscle mass while cutting as much fat as possible. Unlike most fat loss methods, carb cycling provided sustained fat loss, so once you start shedding off that excess fat, you will continue doing so as long as you go through with the system. But there #39;s a catch; carb cycling requires a great deal of mental strength plus a perfectly healthy body. When you are carb cycling, you will be switching between high protein and carb meals on workout days and high protein and fat meals on free days. Overall, there #39;ll be a maximum of four workout days a week, but they are normally three. The aim is to consume 20 percent less calories on free days. Your specific goals will determine the number of calories to consume on workout days. If your goal is to lose weight, then you should consume calories needed for maintenance levels. If you want to keep your weight but shed some fat, then you should consume 20 percent more calories than your maintenance levels. If your goal is gain maximum muscle mass, then you should consume 40 percent more calories than your maintenance levels, and mainly after your training. This is the technique employed in the 4 Cycle Fat Loss Solution, fully customized to individual body weight and needs. As mentioned earlier, this system doesn #39;t restrict foods, so you don #39;t have to worry about depriving yourself of your ...From:carbcyclingdietViews:2 1ratingsTime:02:02More inNews Politics

See the original post:
Carb Cycling Diet | 4 Cycle Fat Loss Solution Review - Video

Anticipating Risks And Organising Risk Regulation
ll4.me Anticipating Risks And Organising Risk Regulation Anticipating risks has become an obsession of the early twenty-first century. Private and public sector organisations increasingly devote resources to risk prevention and contingency planning to manage risk events should they occur. This book shows how we can organise our social, organisational and regulatory policy systems to cope better with the array of local and transnational risks we regularly encounter. Contributors from a range of disciplines - including finance, history, law, management, political science, social psychology, sociology and disaster studies - consider threats, vulnerabilities and insecurities alongside social and organisational sources of resilience and security. These issues are introduced and discussed through a fascinating and diverse set of topics, including myxomatosis, the 2012 Olympic Games, gene therapy and the recent financial crisis. This is an important book for academics and policy makers who wish to understand the dilemmas generated in the anticipation and management of risks. Publisher: Cambridge University Press Illustration: N Language: ENG Title: Anticipating Risks and Organising Risk Regulation Pages: 00320 (Encrypted PDF) On Sale: 2006-08-04 SKU-13/ISBN: 9780521193092 Category: Business Economics : Corporate Finance Category: Business Economics : Management - General Anticipating risks has become an obsession of the early twenty-first century. Private and public sector ...From:renee0636Views:0 0ratingsTime:00:13More inPeople Blogs

Continue reading here:
Anticipating Risks And Organising Risk Regulation - Video

UCLA Researchers Seek New Treatments for "Bubble Boy" Disease
In this KCAL 9 News segment, Dr. Donald Kohn talks about how UCLA scientists are utilizing gene therapy to help children with so called "bubble boy" disease, or SCID (Severe Combined Immunodeficiency Disease). This breakthrough research could have a huge impact on future therapies and treatments.From:UCLAJCCCViews:0 0ratingsTime:01:52More inScience Technology

Read the original here:
UCLA Researchers Seek New Treatments for "Bubble Boy" Disease - Video

DNA2.0, the leading bioengineering solutions provider, today announced a collaboration with the Gene Therapy Program at the Perelman School of Medicine, University of Pennsylvania, to evaluate the impact of gene optimization on in vivo protein expression.

Menlo Park, CA (PRWEB) November 14, 2012

Understanding the gene preferences of differentiated tissues is critical to maximize the efficacy of gene therapies. The Gene Therapy Program, under the direction of James M. Wilson, MD, PhD, professor of Pathology and Laboratory Medicine, focuses on developing effective gene transfer vectors derived from recombinant viruses and their application in the treatment of a variety of acquired and inherited diseases. Much of the program's current effort is in the development and optimization of new adeno-associated virus vectors.

Gene optimization is a viable and under-appreciated method to improve transgene expression in gene therapy, and we are excited to evaluate the technology of DNA2.0 in our vector systems, said Dr. Wilson.

DNA2.0s technology concentrates on the influence of gene design on expression in mammalian cell lines. However, the gene preferences of tissues in vivo may be distinct from cultured production cell lines and may differ between different target tissue.

Dr. Wilsons vaccine research team is a member of the Collaboration for AIDS Vaccine Discovery (CAVD), an international network of scientists and experts dedicated to designing a variety of novel HIV vaccine candidates and advancing the most promising candidates to clinical trials. CAVD is funded by grants from the Bill and Melinda Gates Foundation.

Read more:
DNA2.0 Teams Up With Penn's Gene Therapy Program on Optimizing Gene Expression for HIV-1 Vaccine

My Hair Care Routine Favorite Products
Below are all the items mentioned in the video: Ovation Cell Therapy System (they have the holiday set an use the code survey2012) Organix coconut milk Loreal evercream TRESemme Thermal heat tamer Macadamia Healing Oil TRESemme 4+4 Styling glaze Paul Mitchel firm style dry wax Sexy hair play dirty textureizing hairspray/wax Hair Doughnut from Clairs or Sallys Wide tooth comb Teasing comb/brush (sallys) Revlon Hot air hair styler Like Subscribe 🙂 Don #39;t forget to follow me on Instagram Twitter @The1nonlymaria and now I have my blog.From:The1nonlymariaViews:1 1ratingsTime:19:29More inHowto Style

Read this article:
My Hair Care Routine

What Are Stem Cells | Stem Cell Malaysia
stemcellmalaysia.com Stem cells are non-differentiated cells with the ability to divide and produce any body cell types. The ability of stem cells to differentiate and self-regenerate impart great possibilities for disease treatment other than for restoring health, beauty and anti-aging. Clinically proven for certain illness and conditions, stem cells can now be introduced into the body to repair and replace damaged organ or tissue. For more informative articles on stem cells and stem cell therapy, please visit Stem Cell Malaysia at http:/stemcellmalaysia.com/.From:stemcells2012Views:2 1ratingsTime:06:29More inHowto Style

See more here:
What Are Stem Cells | Stem Cell Malaysia - Video

LITCHFIELDWith a name inspired by a Celtic goddess who could manifest magic for the good of others, an Elkhound mix that suffered the depths of animal abusenearly to the point of deathis benefiting from cutting-edge veterinary medicine at a practice in Bantam.

Rhiannon, whose name derives from the Stevie Nicks song about the legendary goddess, is one of two patients helping to make veterinary history in Connecticut through the states first in-clinic stem cell regenerative therapy treatments.

Such loving care stands in stark contrast to the condition Rhiannons owner, Edward Milne of Cheshire, found the 14-year-old in the first time he saw her.

I found her hanging by her neck from a tree as I was driving along a back country road in Northford, CT when she was about two years old, Mr. Milne wrote in an e-mail to the Bantam clinic, Animal Health Practice Inc.

When I confronted the owner, Mr. Milne wrote, he admitted that he had not fed her or provided her with water for some time, and when she didnt die, he hung her from the tree to finish her off. I guess it was fate that brought us together.

Another type of Rhiannon-esque fate brought the dog to a vet who is performing a ground-breaking procedure to treat severe arthritis in her elbow and back.

Rhiannon is the first dog to receive MediVet Americas non-controversial adipose regenerative stem cell therapy, according to a release sent by the company. MediVet is a global leader in veterinary science located in 29 countries. The company develops advanced cellular treatments and natural herbal remedies designed to maximize animal performance, repair, recovery and general wellness.

Were very excited to be the first veterinarians in Connecticut to offer this new technology, said Dr. Angela Erickson-Greco Monday morning.

In addition to Rhiannon, Dr. Erickson-Greco is also administering the treatment to Dakota, a Bernese Mountain Dog and Great White Pyrenees mix, who has bilateral ACL tears, which means she has torn a crucial ligament in both of her knees.

New Milford resident Cathy Morsey said Dakota had a limp in her front leg in the shoulder area at 6 months old. In January of last year, we had a wet snow and she slid on the snow and tore a cartilage in her knee, said Ms. Morsey. Continued...

Follow this link:
Rhiannon, an Abused Dog, and Dakota, Get Stem Cell Therapy in Litchfield

NEW YORK, Nov. 13, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NBS) ("NeoStem" or the "Company"), an emerging market leader in the fast growing cell therapy industry, today announced that the Company has completed the divestiture of its 51% ownership interest in Suzhou Erye Pharmaceutical Co. Ltd. ("Erye"), a China-based generic pharmaceutical company. The divestiture provides NeoStem with $12,280,000 in cash and removes from the Company's balance sheet over $30 million in short and long-term debt obligations. Erye also returns 1,040,000 shares representing approximately 0.7% of the Company's outstanding common stock, 1,170,000 stock options representing approximately 5.1% of the Company's outstanding options and 640,000 warrants to purchase common stock held by Erye representing approximately 1.1% of the Company's outstanding warrants.

"We are very pleased to have reached this significant milestone in our business," said Dr. Robin Smith, Chairman and CEO of NeoStem. "The Erye divestiture brings non-dilutive capital that bolsters our cash position in the United States, reduces legal and financial reporting expenditures, simplifies our financial statements and focuses our efforts exclusively on the rapidly growing cell therapy industry. The divestiture also paves the way for the Company to qualify for new funding through the National Institutes of Health (NIH) Small Business Innovation Research (SBIR) program which would support our pre-clinical development of VSELTM Technology. NeoStem will also be able to invest more resources into its cell therapy development and contract manufacturing activities."

About NeoStem, Inc.

NeoStem, Inc. continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy industry. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC ("PCT"), with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe this expertise and existing research capabilities and collaborations will enable us to achieve our mission of becoming a premier cell therapy company.

Our contract development and manufacturing service business supports the development of proprietary cell therapy products. NeoStem's most clinically advanced therapeutic product candidate, AMR-001, is being developed at Amorcyte, LLC ("Amorcyte"), which we acquired in October 2011. Amorcyte is developing a cell therapy for the treatment of cardiovascular disease and is enrolling patients in a Phase 2 trial to investigate AMR-001's efficacy in preserving heart function after a heart attack. Athelos Corporation ("Athelos"), which is approximately 80%-owned by our subsidiary, PCT, is collaborating with Becton-Dickinson in the early clinical exploration of a T-cell therapy for autoimmune conditions. In addition, pre-clinical assets include our VSEL TM Technology platform as well as our mesenchymal stem cell product candidate for regenerative medicine. Our service business and pipeline of proprietary cell therapy products work in concert, giving us a competitive advantage that we believe is unique to the biotechnology and pharmaceutical industries. Supported by an experienced scientific and business management team and a substantial intellectual property estate, we believe we are well positioned to succeed.

For more information on NeoStem, please visit http://www.neostem.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's or its partners' successful development of AMR-001 and other cell therapeutics, the size of the market for such products, its competitive position in such markets, the Company's ability to successfully penetrate such markets and the market for its contract development and manufacturing ("CDMO") business, and the efficacy of protection from its patent portfolio, as well as the future of the cell therapeutics industry in general, including the rate at which such industry may grow. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors, including but not limited to matters described under the "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 20, 2012 and in the Company's other periodic filings with the Securities and Exchange Commission, all of which are available on its website. The Company does not undertake to update its forward-looking statements. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

Excerpt from:
NeoStem Closes Divestiture of Its Ownership Interest in Suzhou Erye

THE WOODLANDS, Texas--(BUSINESS WIRE)--

Opexa Therapeutics, Inc. (OPXA), a company developing Tcelna, a novel T-cell therapy for multiple sclerosis (MS), today announced that Health Canada has approved the Company's Clinical Trial Application (CTA). The application was filed with the Biologics and Genetic Therapies Directorate. With this approval by the Canadian Health Authority, Opexa expects to expand its ongoing clinical trial in Secondary Progressive MS (SPMS) patients to include several sites in Canada. The Abili-T trial, a Phase 2b study of Tcelna in subjects with SPMS, is currently enrolling patients in the United States.

To date, over a half of the clinical sites have been initiated and approximately ten percent of subjects have been enrolled. Enthusiasm and support remains strong among the patients and the treatment sites. The trial is expected to enroll 180 patients in approximately 30 sites in the U.S. and Canada and conclude in 2015.

In addition, at the end of September, The United States Adopted Names Council (USANC) officially adopted Tcelnas non-proprietary name, imilecleucel-T. USANC is tri-sponsored by the American Medical Association, the United States Pharmacopeial Convention, and the American Pharmacists Association. USANC aims to standardize drug nomenclature by selecting informative and unique non-proprietary names for all pharmaceuticals marketed in the U.S. The name imilecleucel-T is derived from a set of regulations and guidelines set forth by USANC specific to cellular therapies. The non-proprietary name will be used in conjunction with the brand name, Tcelna, in publications and certain communication material appearing as Tcelna (imilecleucel-T).

We are very pleased with the progress of the Abili-T SPMS clinical trial to date, stated Neil K. Warma, President and CEO of Opexa. The clinical trial sites are being activated as planned and screening of patients for enrollment into the trial is on schedule due to the patients enthusiasm to participate in the trial and the efficient cooperation among the sites, our clinical staff and the various vendors. SPMS represents a market in dire need of new, safe and effective therapies. Currently there is only one FDA-approved treatment in the U.S. and it carries a safety warning that significantly limits its use. With the approval of the regulatory package by the Canadian Health Authority, we have taken another key step in the progress of the Abili-T trial, as it enables us to access large clinical practices that should enhance patient enrollment. Additionally, USANCs acceptance of Tcelnas non-proprietary name supports our rebranding effort and enables us to have more flexibility in meeting submission criteria in certain publications. We are also continuing to focus on securing the necessary capital required to continue and complete the trial, added Mr. Warma.

About SPMS

SPMS is a progressive phase of MS which is characterized by a steady progression of clinical neurological damage with or without relapses. After ten years of disease characterized by relapse events and remitting disability (RRMS), approximately 50 percent of patients will have progressed to SPMS. In SPMS, relapses dissipate over time and subjects experience general progression and increasing disability. It is believed that the resulting neurological damage cannot be reversed.

About Tcelna

Tcelna (imilecleucel-T) is a personalized therapy that is specifically tailored to each patient's disease profile. Tcelna is manufactured using ImmPath, Opexa's proprietary method for the production of a patient-specific T-cell immunotherapy, which encompasses the collection of blood from the MS patient, isolation of peripheral blood mononuclear cells, generation of an autologous pool of myelin-reactive T-cells (MRTCs) raised against selected peptides from myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG) and proteolipid protein (PLP), and the return of these expanded, irradiated T-cells back to the patient. These attenuated T-cells are reintroduced into the patient via subcutaneous injection to trigger a therapeutic immune system response. Opexa believes the potential combination of efficacy, superior safety, excellent tolerability and administration may position Tcelna as an MS treatment of choice as compared to existing therapeutics.

About Opexa

See the rest here:
Opexa Receives Clinical Trial Approval From Health Canada for Novel T-Cell Therapy